Jia Liu, Translational Lead of Early Phase Drug Development at The Kinghorn Cancer Centre, shared a post on LinkedIn:
“Prof Elizabeth Smyth giving insightful summary in novel ADCs including payload diversification via immune-stimulation, degraders, Immuno toxins, and the challenges with stromal targeting ADCs.
Biospecific ADCs hitting clinics and target selection, biomarkers and translational studies done alongside well-designed dose optimization clinical trials with collaboration required.”
More posts featuring Jia Liu.
